Skip to main content
. 2020 Jul 17;83(10):923–930. doi: 10.1097/JCMA.0000000000000389

Fig. 5.

Fig. 5.

Effects of rosiglitazone alone or combined with bexarotene on the cell morphology of BCPAP and follicular thyroid cancer (FTC)-133 cells. A, Thyroid cancer BCPAP cells were treated with 50 μM rosiglitazone (R) alone or in combination with different concentrations of bexarotene (B) under normoxic or hypoxic conditions for 72 h. The cell morphology was observed. B, Thyroid cancer FTC-133 cells were treated with 50 μM R alone or in combination with different concentrations of bexarotene (B) under normoxic or hypoxic conditions for 72 h. The cell morphology was observed.